OncLive
LightNews LightNews
banner
onclive.bsky.social
OncLive
@onclive.bsky.social
920 followers 140 following 2.4K posts
Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.
Posts Replies Media Videos
onclive.bsky.social
This episode of OncLive On Air was filmed LIVE at #CFS25! Hear @benlevylungdoc.bsky.social & Dr Tagawa highlight developments in GU cancer management. Watch the video on our site, or listen wherever you get your podcasts! @weillcornell.bsky.social #kcsm #pcsm
www.onclive.com/view/psma-th...
November 13, 2025 at 9:42 PM
onclive.bsky.social
BREAKING: @fda.gov Approves New Pertuzumab Biosimilar for Select HER2+ Breast Cancer Subtypes

Read more: www.onclive.com/view/fda-app...

#FDAapproved #bcsm #oncology
November 13, 2025 at 7:58 PM
onclive.bsky.social
🎤 Panelists discuss how transplant eligibility should be viewed as a continuum based on frailty rather than a binary decision for patients with #multiplemyeloma. #oncology #cancercare

Watch the full video here! ⬇️
www.onclive.com/view/transpl...
Transplant Eligibility Considerations in Patients With Newly Diagnosed Multiple Myeloma | OncLive
Panelists discuss how transplant eligibility should be viewed as a continuum based on frailty rather than a binary decision, with most patients collecting stem cells but only about 20% receiving delay...
www.onclive.com
November 13, 2025 at 5:53 PM
onclive.bsky.social
FDA Grants 510(k) Clearance to EXENT System for Multiple Myeloma Diagnosis
#oncology #myeloma www.onclive.com/view/fda-gra...
FDA Grants 510(k) Clearance to EXENT System for Multiple Myeloma Diagnosis | OncLive
The FDA granted 510(k) clearance to the EXENT System to aid in the diagnosis of multiple myeloma and related disorders.
www.onclive.com
November 13, 2025 at 4:54 PM
onclive.bsky.social
Efforts to Leverage NaPi2b Are Renewed With Novel ADC in Ovarian Cancer #oncology #ovariancancer
www.onclive.com/view/efforts...
Efforts to Leverage NaPi2b Are Renewed With Novel ADC in Ovarian Cancer | OncLive
Initial activity and safety with the investigational ADC TUB-040 in ovarian cancer have renewed interest in NaPi2b as a target for ADC development.
www.onclive.com
November 13, 2025 at 4:53 PM
onclive.bsky.social
.@fda.gov Accepts NDA For 177Lu-edotreotide for GEP-NETs #oncology www.onclive.com/view/fda-acc...
FDA Accepts NDA For 177Lu-edotreotide for GEP-NETs | OncLive
The NDA seeking approval of 177Lu-edotreotide for the treatment of patients with GEP-NETs has been accepted by the FDA.
www.onclive.com
November 13, 2025 at 4:35 PM
onclive.bsky.social
BREAKING 🚨: @fda.gov Approves Ziftomenib for NPM1+ R/R Acute Myeloid Leukemia

Learn more about the approval here 📰: onclive.com/view/fda-app...

#leusm #oncology #FDAapproved
FDA Approves Ziftomenib for NPM1+ R/R Acute Myeloid Leukemia | OncLive
Ziftomenib has received FDA approval for the treatment of adult patients with relapsed or refractory acute myeloid leukemia harboring an NPM1 mutation.
onclive.com
November 13, 2025 at 3:37 PM
onclive.bsky.social
Emerging ADC Data and Combination Strategies Are Set to Redefine First-Line TNBC Management @texasoncology.bsky.social #bcsm #oncology
www.onclive.com/view/emergin...
Emerging ADC Data and Combination Strategies Are Set to Redefine First-Line TNBC Management | OncLive
Joyce O'Shaughnessy, MD, discusses ways that data with sacituzumab govitecan and Dato-DXd may shift treatment standards for patients with mTNBC.
www.onclive.com
November 12, 2025 at 7:19 PM
onclive.bsky.social
Anito-Cel Emerges as Potential Novel Option in R/R Multiple Myeloma @uscsomg.bsky.social #mmsm #hematology
www.onclive.com/view/anito-c...
Anito-Cel Emerges as Potential Novel Option in R/R Multiple Myeloma | OncLive
Anito-cel produced high ORR and sCR/CR rates in patients with relapsed/refractory multiple myeloma.
www.onclive.com
November 12, 2025 at 7:18 PM
onclive.bsky.social
Tinostamustine Snags FDA Orphan Drug Designation for Malignant Glioma @fda.gov #btsm #oncology
www.onclive.com/view/tinosta...
Tinostamustine Snags FDA Orphan Drug Designation for Malignant Glioma | OncLive
The FDA granted orphan drug designation to tinostamustine for malignant glioma.
www.onclive.com
November 12, 2025 at 5:18 PM
onclive.bsky.social
FDA Grants Fast Track Designation to AVZO-1418/DB-1418 for EGFR+, TKI-Pretreated #NSCLC

www.onclive.com/view/fda-gra...
FDA Grants Fast Track Designation to AVZO-1418/DB-1418 for EGFR+, TKI-Pretreated NSCLC | OncLive
AVZO-1418/DB-1418 has received fast track designation from the FDA for patients with advanced, EGFR-mutant NSCLC following prior therapy with an EGFR TKI.
www.onclive.com
November 12, 2025 at 5:03 PM
onclive.bsky.social
Oncology Experts and AI Advocates Explain the Evolving Role of AI in Insurance Appeals #oncology #AI
www.onclive.com/view/oncolog...
Oncology Experts and AI Advocates Explain the Evolving Role of AI in Insurance Appeals | OncLive
Using AI to automate oncology insurance prior authorization submissions could help lighten the load for health care professionals and speed access to care.
www.onclive.com
November 12, 2025 at 3:38 PM
onclive.bsky.social
Immunotherapy Resistance in Kidney Cancer Driven by Myeloid Cell Signaling @vanallenlab.bsky.social @danafarber.bsky.social #kcsm #oncology
www.onclive.com/view/immunot...
Immunotherapy Resistance in Kidney Cancer Driven by Myeloid Cell Signaling | OncLive
A study combined single-cell RNA sequencing data from patients with RCC to learn about patterns of interferon signaling across cell types in tumors.
www.onclive.com
November 12, 2025 at 3:14 PM
onclive.bsky.social
NALIRIFOX Expands Frontline Options in Metastatic Pancreatic Cancer #oncology #pancreaticcancer
www.onclive.com/view/nalirif...
NALIRIFOX Expands Frontline Options in Metastatic Pancreatic Cancer | OncLive
Dong Kim, MD, discusses the role of NALIRIFOX and other frontline chemotherapy regimens in the pancreatic cancer treatment landscape.
www.onclive.com
November 11, 2025 at 8:27 PM
onclive.bsky.social
CONGRATS Trial Data of Nivolumab ± Relatlimab Highlight Clinical Value of Immunotherapy in TLS+ Soft Tissue #Sarcoma #Oncology 🧬

www.onclive.com/view/congrat...
CONGRATS Trial Data of Nivolumab ± Relatlimab Highlight Clinical Value of Immunotherapy in TLS+ Soft Tissue Sarcoma | OncLive
Nivolumab with or without relatlimab exceeded historical benchmarks in TLS-positive soft tissue sarcoma, validating TLS as a predictive biomarker.
www.onclive.com
November 11, 2025 at 7:20 PM
onclive.bsky.social
MD Anderson Experts Spotlight Key Immunotherapy Advances at 2025 SITC Annual Meeting @mdanderson.bsky.social @sitcancer.bsky.social #SITC25 #oncology
www.onclive.com/view/md-ande...
MD Anderson Experts Spotlight Key Immunotherapy Advances at 2025 SITC Annual Meeting | OncLive
Researchers at The University of Texas MD Anderson Cancer Center shared insights about how the immune system can be trained to improve patient outcomes.
www.onclive.com
November 11, 2025 at 6:56 PM
onclive.bsky.social
Detalimogene Produces 63% CR Rate in BCG-Unresponsive #NMIBC with CIS #oncology

www.onclive.com/view/detalim...
Detalimogene Produces 63% CR Rate in BCG-Unresponsive NMIBC with CIS | OncLive
Findings from the preliminary cohort show 3- and 6-month CR rates of 56% and 62%, respectively, with detalimogene in this patient population.
www.onclive.com
November 11, 2025 at 5:37 PM
onclive.bsky.social
Precision Survivorship Platforms Are Essential for Improved, Equitable Care in Pediatric and AYA #Sarcoma #oncology

www.onclive.com/view/precisi...
Precision Survivorship Platforms Are Essential for Improved, Equitable Care in Pediatric and AYA Sarcoma | OncLive
R. Lor Randall, MD, FACS, advocates for precision-based survivorship models in pediatric/AYA sarcoma to address disparities and improve long-term outcomes.
www.onclive.com
November 11, 2025 at 3:17 PM
onclive.bsky.social
At 3 Years, Eque-Cel Displays Deep and Durable Responses in Relapsed Multiple Myeloma #IMS25 #mmsm #hematology
www.onclive.com/view/at-3-ye...
At 3 Years, Eque-Cel Displays Deep and Durable Responses in Relapsed Multiple Myeloma | OncLive
Long-term data reveal deep remissions with eque-cel, suggesting durable disease control with BCMA-directed CAR T-cell therapy in relapsed multiple myeloma.
www.onclive.com
November 11, 2025 at 1:05 PM
onclive.bsky.social
Early Activity With DB-1305/BNT325 Signals Potential Expansion of TROP-2 ADCs in Pretreated Metastatic TNBC @erikahamilton9.bsky.social #oncology #bcsm
www.onclive.com/view/early-a...
Early Activity With DB-1305/BNT325 Signals Potential Expansion of TROP-2 ADCs in Pretreated Metastatic TNBC | OncLive
Erika P. Hamilton, MD, discusses initial efficacy and safety data with the TROP2-targeted ADC DB-1305/BNT325 in pretreated metastatic TNBC.
www.onclive.com
November 10, 2025 at 8:23 PM
onclive.bsky.social
Lutetium Lu 177 Vipivotide Tetraxetan Enables Some Patients with mCRPC to Avoid Chemotherapy #colorectalcancer #oncology

www.onclive.com/view/lutetiu...
Lutetium Lu 177 Vipivotide Tetraxetan Enables Some Patients with mCRPC to Avoid Chemotherapy | OncLive
Daniel J. George, MD, discusses the role of lutetium Lu 177 vipivotide tetraxetan in metastatic CRPC and patient selection considerations.
www.onclive.com
November 10, 2025 at 7:51 PM
onclive.bsky.social
Pharmacists Play Key Role in Patient Education and Treatment Adherence in CML Management #leusm #oncology www.onclive.com/view/pharmac...
Pharmacists Play Key Role in Patient Education and Treatment Adherence in CML Management | OncLive
Jose Tinajero, PharmD, BCOP, discusses the role of the pharmacist in treatment planning and management in chronic myeloid leukemia.
www.onclive.com
November 10, 2025 at 6:09 PM
onclive.bsky.social
@ucsfcancer.bsky.social Urology Clinicians Present Research Findings at #SurgeWest25 #oncology #prostatecancer

www.onclive.com/view/ucsf-ur...
UCSF Urology Clinicians Present Research Findings at SurgeWest 2025 | OncLive
UCSF clinicians present research at SurgeWest 2025, on an RNA biomarker for prostate cancer and opioid prescribing patterns after urologic surgery.
www.onclive.com
November 10, 2025 at 3:28 PM
onclive.bsky.social
Chan Breaks Down the Need for Dose Escalation With Somatostatin Analogs in GEP-NETs @danafarber.bsky.social @harvardmed.bsky.social @nanets.bsky.social #NANETS25 #medtwitter #oncology www.onclive.com/view/chan-br...
Chan Breaks Down the Need for Dose Escalation With Somatostatin Analogs in GEP-NETs | OncLive
Jennifer Chan, MD, MPH, discusses dose escalation and interval shortening with somatostatin analogs for GEP-NETs and how SORENTO may shape treatment.
www.onclive.com
November 8, 2025 at 8:44 PM
onclive.bsky.social
Yale Study Sheds Light on Cellular Resistance to Osimertinib in Adenocarcinoma @yalecancer.bsky.social #oncology
www.onclive.com/view/yale-st...
Yale Study Sheds Light on Cellular Resistance to Osimertinib in Adenocarcinoma | OncLive
Protein METTL7A plays key role in resistance to drugs targeting EGFR-mutant lung adenocarcinoma.
www.onclive.com
November 7, 2025 at 8:28 PM